Clinical significance of MRI PI-RADS 3 lesions upgraded by dynamic contrast enhancement: the “PI-RADS 3 + 1” subgroup
International Urology and Nephrology · 11.07.2026 · 58 (12) · 5259-5263
DOI: 10.1007/s11255-026-05265-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urology and Nephrology, online erschienen am 11.07.2026. Verfasst von Margaux Poniman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hôpital Nord, Assistance Publique, Hôpitaux de Marseille (AP-HM), Marseille, France. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: PI-RADS (Prostate Imaging Reporting and Data System) category 3 lesions harbor a heterogeneous risk of clinically significant prostate cancer (csPCa). They are less frequently biopsied in contemporary practice. Peripheral zone lesions upgraded from PI-RADS 3 to 4 solely based on dynamic contrast enhancement (DCE) ("PI-RADS 3 + 1") may represent a distinct subgroup. We aimed to assess the prevalence of csPCa in this subset. METHODS: We conducted a single-center study based on a prospectively maintained database, including consecutive patients with a single PI-RADS 3 + 1 lesion identified at our institution who underwent prostate biopsy between November 2023 and November 2025. csPCa was defined as International Society of Urological Pathology (ISUP) grade group ≥ 2. RESULTS: Among 55 patients, prostate cancer was detected in 35 cases (64%), including 16 csPCa (29%). Most biopsies (71%) did not yield csPCa. High-grade disease (ISUP GG ≥ 3) was identified in only two patients (4%). csPCa detection rates were higher in patients with PSAd ≥ 0.15 (39% vs 19%). A PSAd-based strategy would have avoided 49% of biopsies but missed 31% of csPCa cases. PSAd showed modest discrimination (AUC 0.65). Lesion size was not associated with csPCa and demonstrated poor discrimination (AUC 0.41). CONCLUSIONS: PI-RADS 3 + 1 lesions appear to represent an intermediate-risk subgroup between conventional PI-RADS 3 and PI-RADS 4 lesions. csPCa was detected in nearly one-third of patients, supporting individualized biopsy decision-making rather than automatic management as conventional PI-RADS 4 lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Hôpital Nord, Assistance Publique, Hôpitaux de Marseille (AP-HM), Marseille, France.
- Department of Radiology, Hôpital Nord, Assistance Publique, Hôpitaux de Marseille (AP-HM), Marseille, France.
- Department of Urology, Hôpital Nord, Assistance Publique, Hôpitaux de Marseille (AP-HM), Marseille, France. Thibaut.long2@gmail.com.
- Department of Urology, Hôpital d'Instruction Des Armées Sainte-Anne, Toulon, France. Thibaut.long2@gmail.com.
ORCID-Profile: Thibaut Long Depaquit
Zitieren
APA
Poniman, M., Imzourh, A., Bened, H., Chemouni, D., Corral, R., Bastide, C., Baboudjian, M., & Long Depaquit, T. (2026). Clinical significance of MRI PI-RADS 3 lesions upgraded by dynamic contrast enhancement: the “PI-RADS 3 + 1” subgroup. International Urology and Nephrology, 58(12), 5259-5263. https://doi.org/10.1007/s11255-026-05265-3
Vancouver
Poniman M, Imzourh A, Bened H, Chemouni D, Corral R, Bastide C, et al. Clinical significance of MRI PI-RADS 3 lesions upgraded by dynamic contrast enhancement: the “PI-RADS 3 + 1” subgroup. International Urology and Nephrology. 2026;58(12):5259-5263. doi:10.1007/s11255-026-05265-3
BibTeX
@article{Poniman2026,
author = {Poniman, Margaux and Imzourh, Assia and Bened, Hector and Chemouni, David and Corral, Renaud and Bastide, Cyrille and Baboudjian, Michael and Long Depaquit, Thibaut},
title = {Clinical significance of MRI PI-RADS 3 lesions upgraded by dynamic contrast enhancement: the “PI-RADS 3 + 1” subgroup},
journal = {International Urology and Nephrology},
year = {2026},
volume = {58},
number = {12},
pages = {5259--5263},
doi = {10.1007/s11255-026-05265-3}
}
EUVIMED